Publikation

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.

Wissenschaftlicher Artikel/Review - 18.06.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC cancer 2022; 22:672.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
BMC cancer 2022; 22
Veröffentlichungsdatum
18.06.2022
eISSN (Online)
1471-2407
Seiten
672
Kurzbeschreibung/Zielsetzung

F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial.